Key result
cMyBP-C central domain missense mutations drive distinct, site-specific molecular and functional defects.
Why the study?
Hypertrophic cardiomyopathy-associated missense mutations cluster in the central domains of cMyBP-C, suggesting these domains have an active functional role.
Do missense mutations in the central domains (C3-C6) of cardiac myosin binding protein-C (E542Q, G596R, N755K, R820Q) alter protein stability, actomyosin interaction, and sarcomeric localization compared to wild-type cMyBP-C in vitro?
Do missense mutations in the central domains (C3-C6) of cardiac myosin binding protein-C (E542Q, G596R, N755K, R820Q) alter protein stability, actomyosin interaction, and sarcomeric localization compared to wild-type cMyBP-C in vitro?
This preclinical study demonstrates that HCM-associated missense mutations in the central C3-C6 domains of cMyBP-C impair its function as a contractile brake through distinct, mutation-specific molecular mechanisms including altered thin/thick filament binding, mislocalization, or protein instability.
Answers are grounded in this paper and cite their sources.
Mutation-specific cMyBP-C defects may drive HCM; hypothesis-generating and should not yet change practice.
Myosin binding protein-C (MyBP-C) is a multidomain protein that regulates muscle contraction. Mutations in MYBPC3, the gene encoding for the cardiac variant (henceforth called cMyBP-C), are amongst the most frequent causes of hypertrophic cardiomyopathy. Most mutations lead to a truncated version of cMyBP-C, which is most likely unstable. However, missense mutations have also been reported, which tend to cluster in the central domains of the cMyBP-C molecule. This suggests that these central domains are more than just a passive spacer between the better characterized N- and C-terminal domains. Here, we investigated the potential impact of four different missense mutations, E542Q, G596R, N755K, and R820Q, which are spread over the domains C3 to C6, on the function of MyBP-C on both the isolated protein level and in cardiomyocytes in vitro. Effect on domain stability, interaction with thin filaments, binding to myosin, and subcellular localization behavior were assessed. Our studies show that these missense mutations result in slightly different phenotypes at the molecular level, which are mutation specific. The expected functional readout of each mutation provides a valid explanation for why cMyBP-C fails to work as a brake in the regulation of muscle contraction, which eventually results in a hypertrophic cardiomyopathy phenotype. We conclude that missense mutations in cMyBP-C must be evaluated in context of their domain localization, their effect on interaction with thin filaments and myosin, and their effect on protein stability to explain how they lead to disease.
No takes yet. Share an insight, caveat, or question.
Pearce et al. (2023) studied Hypertrophic cardiomyopathy (HCM). cMyBP-C central domain (C3C6) missense mutations (E542Q, G596R, N755K, and R820Q) vs. Wild-type (WT) cMyBP-C (C3C6 multidomain or full-length constructs) was evaluated on Protein domain stability, aggregation, binding to myosin S1, actomyosin ATPase activity, thin filament association, and sarcomeric localization. Missense mutations in cMyBP-C central domains cause site-specific defects, with E542Q and G596R increasing actomyosin ATPase activity by 50% and 30%, N755K causing mislocalization, and R820Q failing to express.
Synapse has enriched 10 related papers. Consider them for comparative context: